Cardiff Oncology Inc. (CRDF)
NASDAQ · Healthcare
Cardiff Oncology Inc. EBITDA 2011–2025
Cardiff Oncology Inc. annual/quarterly ebitda history and growth rate from 2011 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Cardiff Oncology Inc. ebitda for the quarter ending March 31, 2026 was -12.8 M, a 10.68% decrease year-over-year.
- Cardiff Oncology Inc. ebitda for the twelve months ending March 31, 2026 was -49.8 M, a 105.92% increase year-over-year.
- Cardiff Oncology Inc. annual ebitda for 2025 was -48.6 M, a 0.72% increase from 2024.
- Cardiff Oncology Inc. annual ebitda for 2024 was -48.2 M, a 7.18% increase from 2023.
- Cardiff Oncology Inc. annual ebitda for 2023 was -45.0 M, a 13.48% increase from 2022.
- Cardiff Oncology Inc. annual ebitda for 2022 was -39.7 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Cardiff Oncology Inc. EBITDA — FAQ
Cardiff Oncology Inc. (CRDF) ebitda over the last 15 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CRDF's ebitda history?
The chart and table above show Cardiff Oncology Inc.'s ebitda by year and by quarter, including the growth rate.